当前位置: X-MOL 学术J. Nat. Prod. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Antineoplastic Agents. 604. The Path of Quinstatin Derivatives to Antibody Drug Conjugates
Journal of Natural Products ( IF 3.3 ) Pub Date : 2017-09-12 00:00:00 , DOI: 10.1021/acs.jnatprod.7b00237
George R. Pettit 1 , Noeleen Melody 1 , Jean-Charles Chapuis 1
Affiliation  

To further evaluate the exceptional cancer cell growth inhibition by the quinstatins, of which one of the series, quinstatin 8, approaches the exceptional cytotoxic activity of the parent dolastatin 10 (1), four of the quinstatins have been converted to desmethyl derivatives. Three of the four (4, 5, and 8 [7bd]) were next bonded to the linker (8) employed in the synthesis of the very successful and structurally related anticancer drug Adcetris (3). Owing to these structural modifications, a next step could be taken by bonding to a monoclonal antibody, thereby producing an antibody drug conjugate (ADC) related to Adcetris structurally but with the possibility of a wider spectrum of activity and utility.

中文翻译:

抗肿瘤药。604. Quinstatin衍生物通往抗体药物结合物的路径

为了进一步评估喹他汀类药物对癌细胞生长的异常抑制作用,其中的一种,奎他汀类药物8,接近亲代多士汀10(1)的异常细胞毒活性,其中四种喹他汀类药物已被转化为去甲基衍生物。接下来,将四个中的三个(4、5和8 [ 7b - d ])键合至用于合成非常成功且结构相关的抗癌药物Adcetris(3)的接头(8)。由于这些结构修饰,下一步可以通过与单克隆抗体结合来进行,从而在结构上产生与Adcetris有关的抗体药物缀合物(ADC),但可能具有更广泛的活性和实用性。
更新日期:2017-09-12
down
wechat
bug